Cornell Stamoran, Ph.D.
Catalent Institute Board Member, Vice President, Strategy & Corporate Development, Catalent Pharma Solutions
Dr. Stamoran has spent nearly 25 years engaged with the healthcare industry, and has experienced the realities of patient adherence and outcomes enhancement from almost every stakeholder perspective: from direct engagement with retail and hospital pharmacists; medical professionals; specialty pharmacies and clinics; and pharmacy benefit managers and payers. He has directly participated in adherence and outcomes enhancement strategies for more than 150 drugs over the last 10 years.
Dr. Claus-Michael Lehr
Professor & Head, Dept. of Drug Delivery (DDEL)
Dr. Claus-Michael Lehr, professor and head of the department of drug delivery (DDEL), Saarland University and advisory board member of Catalent Institute has spent more than 15 years leading research into ways to overcome biological barriers to effective drug delivery, and the development and formulation of appropriate carriers to transport active pharmaceutical and biopharmaceutical molecules to desired targets. He has co-authored many notable publications on the development of sophisticated in-vitro models that more accurately represent the epithelial cells and tissues concerned in transport, and the application of nanotechnology to improve in-vivo delivery to such therapeutic targets.
Global Pharma & Medical Ingredients,
BASF Chemical Company
Andreas is supporting BASF’s activities in hot-melt extrusion technology. Andreas’ expertise is mainly on Solubility Enhancement, controlled release systems, low temperature melt extrusion prohnology from University of Applied Sciences Magdeburg in 1999. Andreas Gryczke has co-authored 8 research papers, book chapter, 8 patents and numerous conference abstracts. He is invited reviewer for the European Journal of Pharmaceutics and Biopharmaceutics. Andreas is member of International Association for Pharmaceutical Technology and he is member of the American Association of Pharmaceutical Scientists.
Dr. Uwe Hanenberg
R&D Director, Catalent Pharma Solutions
Uwe holds a PhD degree in Pharmacy and is certified specialized pharmacist for pharmaceutical analytics (Fachapotheker). Uwe has a broad background of pharmaceutical science and held functional and leadership roles in Quality, Operations and R&D at Altana, Grünenthal and Catalent. He is a specialist in oral solid dosage forms and modified release technologies. Uwe is member in the APV and DPG.
Dr. Filipe Gaspar
Senior Director of Particle Engineering Services, Hovione
Filipe holds a Ph.D. in Chemical Engineering from the University of Birmingham, UK. Before joining Hovione he worked in particle engineering using supercritical fluids. At Hovione he led the implementation of spray drying and then directed the R&D group that developed further the technology. He was involved in +120 projects and was the lead scientist of several projects that reached commercial stage, including the first at Hovione submitted under Quality by Design. Before becoming a business leader, he was the Director of Drug Product Technologies with responsibility for selection and implementation of new technologies within the company.
Dr. Kirsty Gapp
TDD platform leader, 3M
Dr. Gapp’s background is in molecular biology and microbiology. She has held various technical and commercial roles within 3M Health Care focusing mainly on medical devices. Dr. Gapp’s current role is overseeing 3M’s Transdermal Drug Delivery platform in EMEA, including microneedle technology.
Dr. Marshall Crew
President and CEO, Agere Pharmaceuticals
Dr. Marshall Crew has 17 years of experience improving oral bioavailability with solubilization technologies. Marshall has spent his career developing technologies for the delivery of poorly soluble drugs, and then managing their application to achieve client success. Recognized as an innovator in drug delivery and solubilization, he has over 28 patents and patent applications to his name on various drug delivery platforms including controlled release, nanotechnology and solid dispersions. His scientific expertise includes formulation design and development, solid state characterization of drug substance and product, and computational modeling (predicting shelf-life and pharmacokinetic and bioavailability for oral, devices and parenteral delivery). Marshall holds a PhD in Physical Chemistry from Oregon State University, and is a member of Agere’s Board of Directors.